Valuation: Vericel Corporation

Market Cap 2.79B 2.5B 2.28B 2.09B 3.93B 262B 4.05B 27.54B 10.98B 140B 10.46B 10.24B 441B P/E 2026 *
72.3x
P/E 2027 * 54.6x
Enterprise Value 2.79B 2.5B 2.28B 2.09B 3.93B 262B 4.05B 27.54B 10.98B 140B 10.46B 10.24B 441B EV / Sales 2026 *
8.1x
EV / Sales 2027 * 7.01x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day+5.48%
1 week+35.67%
Current month+35.67%
1 month+34.07%
3 months+21.14%
6 months+55.48%
Current year+51.68%
1 week 39.44
Extreme 39.44
55.6
1 month 39
Extreme 39
55.6
Current year 28.95
Extreme 28.95
55.6
1 year 28.95
Extreme 28.95
55.6
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2
Extreme 2
68.94
Manager TitleAgeSince
Chief Executive Officer 62 01/03/2013
Director of Finance/CFO 51 25/01/2021
Chief Tech/Sci/R&D Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 71 28/09/2005
Chairman 75 05/10/2012
Director/Board Member 57 23/08/2013
Date Insider Type Main position Quantity % Market Cap. Importance
12/08/26 Exercice

Director

21,000 0.0411%
03/08/26 Exercice

Chief Operating Officer

30,000 0.0587%
30/07/26 Exercice

Controller/Auditor

13,500 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
+5.48%+35.67%+40.27%+49.60% 2.79B
-0.79%-4.48%+46.48%+125.69% 1,206B
+1.43%+1.11%+48.05%+83.05% 665B
+1.07%-1.21%+32.92%+104.92% 515B
-0.36%-3.25%+45.42%+65.10% 381B
-0.14%-1.87%+70.06%+41.09% 362B
-0.78%-0.52%+30.47%+58.09% 307B
-0.80%-0.21%+7.98%+36.17% 289B
+0.03%-1.20%+43.79%+69.83% 249B
-0.41%-2.22%+40.43%+107.03% 207B
Average +0.47%+2.18%+40.59%+74.06% 418.25B
Weighted average by Cap. -0.04%-1.93%+42.71%+88.09%

Financials

2026 *2027 *
Net sales 344M 309M 282M 257M 485M 32.34B 500M 3.4B 1.36B 17.26B 1.29B 1.26B 54.48B 398M 357M 326M 298M 561M 37.39B 578M 3.93B 1.57B 19.95B 1.49B 1.46B 62.98B
Net income 39.97M 35.85M 32.76M 29.91M 56.35M 3.76B 58.12M 395M 157M 2B 150M 147M 6.33B 51.45M 46.14M 42.17M 38.5M 72.53M 4.84B 74.81M 508M 203M 2.58B 193M 189M 8.15B
Net Debt - -
Projected Income Statement - Annual - Vericel Corporation
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
06/11/26 $54.62 +5.48% 1,616,567
05/11/26 $51.78 +13.85% 2,682,493
04/11/26 $45.48 +10.68% 1,807,628
03/11/26 $41.09 +1.43% 635,184
02/11/26 $40.51 +0.62% 684,368
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Vericel Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
54.62USD
Average target price
59.71USD
Spread / Average Target
+9.33%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Vericel Corporation
  1. Stock Market
  2. Stocks
  3. VCEL Stock